EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae

Arunkumar Karunanidhi, Nidhi Singh, Jackson V Watkins, Nicholas M Smith iD, Yanan Zang, Xindi Shan, Gilberto Espinoza, Jian Li iD, Yinzhi Lang, Jürgen B Bulitta, Zackery P Bulman iD

Antimicrobial Agents and Chemotherapy · 04.03.2026 · 70 (3)

DOI: 10.1128/aac.01540-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 04.03.2026. Verfasst von Arunkumar Karunanidhi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Ceftazidime, Aztreonam, Klebsiella pneumoniae, Azabicyclo Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy And Infectious Diseases of the National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an urgent need for additional therapeutic solutions to treat serious bacterial infections caused by metallo-β-lactamase (MBL)-producing Klebsiella pneumoniae . Aztreonam, when partnered with ceftazidime/avibactam, has in vitro activity against most MBL-producing K. pneumoniae , but clinical outcomes may be suboptimal. The purpose of this study was to determine if aminoglycosides can enhance the pharmacodynamic activity of ceftazidime/avibactam plus aztreonam against MBL-producing K. pneumoniae . K. pneumoniae isolates harboring MBL genes ( bla NDM , bla VIM , and bla IMP ) were evaluated in time-kill assays ( n = 4 isolates) and the hollow fiber infection model (HFIM, n = 2 isolates). Clinically relevant doses of antibiotics were simulated in the HFIM, and observed antibiotic exposures represented the upper end of the expected patient plasma concentrations. Resistance was tracked during the HFIM, and confocal microscopy was used to assess cell morphology following antibiotic exposure. Both ceftazidime/avibactam + aztreonam and plazomicin were effective individually at reducing viable bacterial counts of susceptible MBL-producing K. pneumoniae , particularly in the HFIM. Combination regimens with aminoglycosides (amikacin or plazomicin) occasionally demonstrated synergy using traditional definitions based on viable colony counting, but they were able to consistently reduce bacterial turbidity and the emergence of filamentous cells that were observed during exposure to ceftazidime/avibactam + aztreonam. Combinations between ceftazidime/avibactam, aztreonam, and an aminoglycoside are a potentially promising therapeutic strategy to combat the rising threat posed by MBL-producing K. pneumoniae .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAztreonamKlebsiella pneumoniaeAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial AgentsAminoglycosidesMicrobial Sensitivity TestsDrug CombinationsHumansKlebsiella InfectionsThird Generation CephalosporinsDrug Synergism

Stichwörter der Autor:innen

Klebsiella pneumoniaeamikacinaztreonamceftazidime/avibactamcombinationshollow fiber infection modelmetallo-β-lactamaseplazomicin

Substanzen

CeftazidimeAztreonamAzabicyclo Compoundsbeta-LactamasesAnti-Bacterial Agentsavibactam, ceftazidime drug combinationDrug CombinationsAminoglycosidesThird Generation Cephalosporins

Autor:innen und Institutionen

  • Department of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Chicago, Illinois, USA.
  • Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA.
  • Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
  • Department of Microbiology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Nicholas M Smith, Jian Li, Zackery P Bulman

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy And Infectious Diseases of the National Institutes of Health

Zitieren

APA

Karunanidhi, A., Singh, N., Watkins, J. V., Smith, N. M., Zang, Y., Shan, X., Espinoza, G., Li, J., Lang, Y., Bulitta, J. B., & Bulman, Z. P. (2026). Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 70(3). https://doi.org/10.1128/aac.01540-25

Vancouver

Karunanidhi A, Singh N, Watkins JV, Smith NM, Zang Y, Shan X, et al. Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2026;70(3). doi:10.1128/aac.01540-25

BibTeX
@article{Karunanidhi2026,
  author = {Karunanidhi, Arunkumar and Singh, Nidhi and Watkins, Jackson V and Smith, Nicholas M and Zang, Yanan and Shan, Xindi and Espinoza, Gilberto and Li, Jian and Lang, Yinzhi and Bulitta, Jürgen B and Bulman, Zackery P},
  title = {Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing Klebsiella pneumoniae},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  volume = {70},
  number = {3},
  doi = {10.1128/aac.01540-25}
}
Kostenlos starten →